First AD

Second AD

Insights Into Ongoing Investigational Studies in Lung LCNEC

Please briefly describe and provide any thoughts for ongoing lung LCNEC trials, with both familiar and novel agents:

Phase 2 LCNEC-ALPINE atezolizumab + EP, 1L

Phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific ab, 2L+

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Treatment and Management of Lung Large Cell Neuroendocrine Carcinoma (LCNEC)  

Panelists discuss ongoing lung large cell neuroendocrine carcinoma (LCNEC) trials involving both familiar and novel agents, including phase 2 durvalumab + EP (1L), phase 2 LCNEC-ALPINE atezolizumab + EP (1L), phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific antibody (2L+), and phase 1 LB2102 DLL2-directed CAR T (2L+).

Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro

An Overview of the Molecular Characterization of Lung LCNEC